Key takeawaysResearchers and scientists have engineered a new class of supercharged T cells that are stronger, longer-lasting ...

Talquetamab delivers high response rates in refractory myeloma; learn how to prevent skin, nail and oral side effects to stay on therapy. As the therapeutic arsenal for relapsed/refractory multiple ...

After a strong start to the year, the value of biotech financings has tailed off a little, but March has seen a clutch of $50 ...

Severe CRS appeared numerically less frequent than in ZUMA-3, suggesting potential differences in patient selection, supportive care, grading, or real-world mitigation strategies. Tocilizumab and ...